This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cipollone, F. Articles by Patrono, C. Search for Related Content PubMed PubMed Citation Articles by Cipollone, F. Articles by Patrono, C. Related Collections Acute coronary syndromes

(Circulation. 2000;102:1007.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina

Francesco Cipollone, MD; Giovanni Ciabattoni, MD; Paola Patrignani, PhD; Massimo Pasquale, MD; Domenico Di Gregorio, MD; Tonino Bucciarelli, MD; Giovanni Davì, MD; Franco Cuccurullo, MD; Carlo Patrono, MD

From the Departments of Medicine and Aging (F. Cipollone, P.P., M.P., G.D., F. Cuccurullo, C.P.) and Biomedical Sciences (T.B.), University of Chieti "G. D’Annunzio" School of Medicine, Chieti, Italy; Department of Pharmacology (G.C.), Catholic University School of Medicine, Rome, Italy; and the Division of Cardiology (D. Di G.), "F. Renzetti" Hospital, Lanciano, Italy.

Correspondence to Carlo Patrono, MD, Dipartimento di Medicina e Scienze dell’Invecchiamento, Università degli Studi "G. D’Annunzio," Via dei Vestini 31, 66013 Chieti, Italy. E-mail cpatrono{at}unich.it

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Unstable angina is associated with enhanced lipid peroxidation and reduced antioxidant defenses. We have previously reported aspirin failure in the suppression of enhanced thromboxane (TX) biosynthesis in a subset of episodes of platelet activation in this setting. We tested the hypothesis that the in vivo formation of the F₂-isoprostane 8-iso-prostaglandin (PG)F₂, a bioactive product of arachidonic acid peroxidation, is enhanced in unstable angina and contributes to aspirin-insensitive TX biosynthesis.

Methods and Results—Urine samples were obtained from patients with unstable angina (n=32), stable angina (n=32), or variant angina (n=4) and from 40 healthy subjects for the measurement of immunoreactive 8-iso-PGF₂ and 11-dehydro-TXB₂. 8-Iso-PGF₂ excretion was significantly higher in patients with unstable angina (339±122 pg/mg creatinine) than in matched patients with stable angina (236±83 pg/mg creatinine, P=0.001) and control subjects (192±71 pg/mg creatinine, P<0.0001). In patients with unstable angina, 8-iso-PGF₂ was linearly correlated with 11-dehydro-TXB₂ excretion (=0.721, P<0.0001) and inversely correlated with plasma vitamin E (=-0.710, P=0.004). Spontaneous myocardial ischemia in patients with variant angina or ischemia elicited by a stress test in patients with stable angina was not accompanied by any change in 8-iso-PGF₂ excretion, thus excluding a role of ischemia per se in the induction of increased F₂-isoprostane production.

Conclusions—These findings establish a putative biochemical link between increased oxidant stress and aspirin-insensitive TX biosynthesis in patients with unstable angina and provide a rationale for dose-finding studies of antioxidants in this setting.

Key Words: angina • aspirin • isoprostanes • thromboxane • oxidant stress

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The association among oxidative modifications of LDL,^{1 2} reduced antioxidant defenses,³ and unstable angina has been well documented. Moreover, numerous studies have shown that the dietary intake of vitamin E is inversely correlated with the risk of cardiovascular disease⁴ and that vitamin E supplementation reduced nonfatal coronary events in a randomized clinical trial in patients with coronary artery disease.⁵

Recently, a series of bioactive prostaglandin (PG)F₂-like compounds (isoprostanes) have been discovered⁶ that are produced from arachidonic acid through a nonenzymatic process of lipid peroxidation, catalyzed by oxygen free radicals on cell membranes and LDL particles. Among these products, of particular interest is 8-iso-PGF₂ (also known as iPF₂-III), which induces vasoconstriction and amplifies the response of human platelets to other agonists (for a review, see Patrono and FitzGerald⁷ ). F₂-isoprostanes can be reliably measured in both plasma and urine^{8 9} and have been shown to be increased in association with cigarette smoking,^{10 11} diabetes mellitus,¹² and hypercholesterolemia.^{13 14} Consistent with the hypothesis of a contribution of 8-iso-PGF₂ to persistent platelet activation in these settings, dose-dependent suppression of F₂-isoprostane formation by vitamin E supplementation was associated with significant reductions in 11-dehydro-thromboxane (TX)B₂ (TXM) excretion in diabetic¹² and hypercholesterolemic¹³ patients.

Episodic increases in TXA₂ biosynthesis have been reported in patients with unstable angina.^{15 16} Enhanced TX biosynthesis in this setting is likely to reflect episodes of platelet activation, because it was largely suppressed with low-dose aspirin.¹⁶ However, despite >95% suppression of the cyclooxygenase (COX) activity of platelet prostaglandin H synthase (PGHS-1) by aspirin, incomplete suppression of TXM excretion has been detected in some patients with unstable angina.¹⁶

We speculated that increased oxidant stress in unstable angina could induce the generation of 8-iso-PGF₂ and other biologically active isoeicosanoids and that these compounds could in turn contribute to aspirin-insensitive TX biosynthesis in this setting. Therefore, in the present study, we investigated whether 8-iso-PGF₂ formation is altered in patients with severe unstable angina compared with matched patients with stable angina and healthy subjects and whether it correlates with the rate of TXA₂ biosynthesis. Additional studies were performed to assess the influence of myocardial ischemia per se and COX-1 or -2 inhibition on 8-iso-PGF₂ and TXA₂ biosynthesis.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subjects
Between February 1993 and June 1998, we studied 32 patients with severe unstable angina (Braunwald class IIIB¹⁷ ), 32 patients with chronic stable angina, 4 patients with active variant angina, and 40 healthy volunteers. None of the participating subjects were taking vitamins, dietary supplements, or drugs with known antioxidant activity during the study. Conventional therapy was allowed as determined with clinical judgment. Informed consent was obtained from each subject. The study protocol was approved by the institutional ethics committee. The baseline clinical characteristics of patients are given in the Table.

View this table: [in this window] [in a new window]   Table 1. Baseline Characteristics of Study Patients With Ischemic Heart Disease

Study Design
We conducted a cross-sectional comparison of urinary 8-iso-PGF₂ and TXM in patients with unstable angina (n=20) or stable angina (n=20) and 40 age- and gender-matched control subjects (22 men and 18 women, mean age 54±8 years). Moreover, patients with stable and unstable angina were also matched for hypercholesterolemia, diabetes, cigarette smoking, hypertension, and drug therapy to minimize potential confounders (Table ). Each patient underwent an overnight urine collection. Urine samples were added with the antioxidant 4-hydroxy-tempo (1 mmol/L; Sigma Chemical Co) and stored at -20°C until extraction.

To assess the potential influence of myocardial ischemia on F₂-isoprostane and TX biosynthesis, 2 additional studies were performed. In the first, 12 men with stable angina (mean age 62±7 years) were studied. On admission, these patients were monitored with Holter monitoring during the first day of hospitalization to exclude the presence of spontaneous myocardial ischemia. Patients were subjected to an exercise stress test with bicycle ergometry during continuous 12-lead ECG monitoring to assess the relation of 8-iso-PGF₂ excretion to the occurrence of myocardial ischemia. Four consecutive 6-hour urine samples were collected during the first 24 hours of study, and 2 consecutive urine samples (at 30 minutes and 6 hours, respectively) were collected after exercise-induced myocardial ischemia. In the second study, we measured 8-iso-PGF₂ in 46 urine samples collected from 4 patients with active variant angina during 96 hours of observation.

Because small amounts of 8-iso-PGF₂ can be formed by human platelets and monocytes through a COX-1– and -2–dependent mechanism,⁷ respectively, we also evaluated whether the inhibition of COX had any influence on 8-iso-PGF₂ excretion. Thus, to explore the potential contribution of platelet COX-1, we measured 8-iso-PGF₂ and TXM in 47 urine samples collected from 8 patients with stable angina (mean age 62±7 years) taking low-dose aspirin (100 mg/d) and compared it with 17 samples obtained from 4 patients with stable angina (mean age 63±7 years) who were not taking any antiplatelet drug at the time of study due to contraindications. To evaluate the potential contribution of monocyte COX-2, 12 patients with unstable angina (6 men and 6 women, mean age 64±11 years) were randomly assigned to receive (1) conventional therapy plus 1 mg/kg 6-methyl-prednisolone (6-MP) BID for 2 days, administered in a 25-minute intravenous infusion (n=6) or (2) conventional therapy plus placebo (as 0.9% NaCl solution) BID for 2 days (n=6). All patients received 100 mg/d aspirin during the study. Twelve 6-hour urine samples were collected from each patient, and a total of 144 urine samples were analyzed for 8-iso-PGF₂ and TXM.

To investigate the relationship between endogenous plasma antioxidants and F₂-isoprostane biosynthesis, blood and urine samples were obtained from 14 patients with severe unstable angina (7 men and 7 women, mean age 54±9 years) after a 12-hour fast for the determination of plasma vitamin E and urinary 8-iso-PGF₂. Blood was drawn into test tubes that contained EDTA (2.7 mmol/L) and were separated within 1 hour after sampling. Vitamin E plasma content was determined with HPLC.¹⁸

Urinary Eicosanoid Assays
Urinary 8-iso-PGF₂ and TXM levels were measured according to previously described and validated radioimmunoassay methods.^{9 19}

Statistical Analysis
For the clinical data, variables were compared with the use of the ² test. The biochemical data were analyzed according to nonparametric methods. An ANOVA was performed with the Kruskal-Wallis method. Subsequent pairwise comparisons were made with the Mann-Whitney U test with corrections for multiple comparisons. The differences between baseline and postprocedural values were analyzed with the Wilcoxon signed-rank test. Moreover, the association of eicosanoid measurements with other biochemical parameters was assessed with the Spearman rank correlation test. The number of ischemic episodes and the ischemic burden are expressed as median and range; the remaining variables are reported as mean±SD. Statistical significance was considered to be indicated by a P value of <0.05, except for multiple comparisons, where the threshold for statistical significance was defined on the basis of the number of comparisons.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Urinary 8-iso-PGF₂ excretion was significantly higher in patients with unstable angina (339±122 pg/mg creatinine, mean±SD, n=20) than in matched patients with stable angina (236±83 pg/mg creatinine, n=20, P=0.001) and in healthy subjects (192±71 pg/mg creatinine, n=40, P<0.0001) (Figure 1).

View larger version (13K): [in this window] [in a new window]   Figure 1. Mean±SD rates of excretion of 8-iso-PGF2 measured in patients with unstable angina or chronic stable angina and in healthy subjects. Patients with stable and unstable angina were matched for a number of variables that could affect the rate of lipid peroxidation.

Patients with unstable angina taking low-dose aspirin had significantly higher TXM excretions than did patients with stable angina (532±227 versus 194±89 pg/mg creatinine, n=20, P<0.0001) (Figure 2). A statistically significant correlation was found between 8-iso-PGF₂ and TXM excretion in patients with unstable angina (=0.721, P<0.0001) (Figure 3) but not in patients with stable angina or healthy subjects (not shown). Moreover, as shown in Figure 4, a statistically significant inverse correlation was found between plasma levels of vitamin E and urinary 8-iso-PGF₂ (=-0.710, P=0.004) and TXM (=-0.696, P=0.006) in patients with unstable angina.

View larger version (10K): [in this window] [in a new window]   Figure 2. Urinary excretion rates of 11-dehydro-TXB2 in matched patients with unstable angina and chronic stable angina. •, Individual measurements. Horizontal lines represent mean values for each group.

View larger version (14K): [in this window] [in a new window]   Figure 3. Correlation between urinary excretion rates of 8-iso-PGF2 and 11-dehydro-TXB2 in patients with severe unstable angina.

View larger version (11K): [in this window] [in a new window]   Figure 4. Correlation between plasma levels of vitamin E and urinary excretion rates of 8-iso-PGF2 (top) and 11-dehydro-TXB2 (bottom) in patients with unstable angina.

Effects of Myocardial Ischemia
By investigating 8-iso-PGF₂ excretion before and after a positive exercise stress test in 12 patients with chronic stable angina, we sought to determine whether myocardial ischemia per se was responsible for triggering the enhanced biosynthesis of F₂ isoprostanes. Urinary 8-iso-PGF₂ did not increase as a result of myocardial ischemia, as reflected with values of 234±128 (n=48) before and 219±111 (n=24) pg/mg creatinine after effort-induced myocardial ischemia (P=NS) (Figure 5). Moreover, to exclude that the severity of ischemia caused by effort in stable patients could be insufficient to cause detectable lipid peroxidation, we also measured 8-iso-PGF₂ excretion in 4 patients with active variant angina. During the first 24 hours of Holter monitoring, all patients with variant angina and 23 of 32 patients with unstable angina had at least 1 ischemic episode. Both the number of ischemic episodes (median 8 and range 1 to 10 versus median 1 and range 0 to 3 per patient) and the total ischemic burden (median 39 and range 3 to 112 versus median 18 and range 0 to 63 minutes per patient) were greater in patients with variant angina than in patients with unstable angina. Despite this, the level of lipid peroxidation in patients with variant angina was comparable to that of patients with stable angina and lower than of patients with unstable angina. Moreover, in patients with variant angina, 8-iso-PGF₂ excretion did not differ between the samples collected during myocardial ischemia (249±119 pg/mg creatinine, n=19) and those collected during the ischemia-free periods (262±129 pg/mg creatinine, n=27).

View larger version (13K): [in this window] [in a new window]   Figure 5. Effect of effort-induced myocardial ischemia on urinary excretion of 8-iso-PGF2. Excretion rates were measured in 12 patients with chronic stable angina on 2 consecutive days before and after a positive exercise stress test.

Effects of COX Inhibition
Because relatively small amounts of 8-iso-PGF₂ can be formed enzymatically through the COX activity of platelet PGHS-1 and monocyte PGHS-2, we explored the effects of COX inhibition on the urinary excretion of 8-iso-PGF₂. Thus, we used aspirin and 6-MP to investigate the mechanism or mechanisms of F₂-isoprostane formation in ischemic heart disease. Aspirin irreversibly acetylates the serine residue at position 529 (Ser529) in the polypeptide chain of PGHS-1.²⁰ By virtue of this unique mechanism of action, the daily intake of low doses of aspirin selectively suppresses platelet TXA₂ synthesis in a cumulative fashion.²¹ As shown in Figure 6, urinary 8-iso-PGF₂ excretion was not significantly different in patients with stable angina treated with low-dose aspirin versus those untreated with low-dose aspirin, despite a statistically significant difference in TXM excretion.

View larger version (12K): [in this window] [in a new window]   Figure 6. Urinary excretion rates of 8-iso-PGF2 (left) and 11-dehydro-TXB2 (right) in patients with stable angina with chronic aspirin (ASA) therapy compared with those not taking any antiplatelet treatment. Platelet COX inhibition, as reflected by suppression of TX biosynthesis, was not associated with any detectable difference in urinary 8-iso-PGF2. Numbers in parentheses represent number of urine samples from which mean value for each group was derived.

Previous in vitro evidence demonstrates that glucocorticoids can prevent inducible monocyte 8-iso-PGF₂ production in association with the suppression of PGHS-2 induction.²² The excretion rates of urinary 8-iso-PGF₂ measured before, during, and after 6-MP or placebo infusions are depicted in Figure 7. In patients randomized to receive 6-MP, 8-iso-PGF₂ formation did not show any statistically significant change between the first and the last day of study (252±169 versus 215±147 pg/mg creatinine). Moreover, no statistically significant differences were found between placebo and 6-MP treatment. These findings are consistent with a COX-independent mechanism of F₂-isoprostane formation in unstable angina.

View larger version (22K): [in this window] [in a new window]   Figure 7. Time course of urinary 8-iso-PGF2 excretion during the 3 days of study before and after randomization of 12 unstable angina patients to intravenous 6-MP or intravenous placebo. Columns and vertical lines represent mean+SD values.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Previous studies have examined the role of lipid peroxidation in acute coronary syndromes through the measurements of malondialdehyde¹ or the susceptibility of the LDL of the patient to oxidation in vitro.² However, malondialdehyde is a byproduct of COX activity in platelets,²³ thus resulting in lack of specificity in clinical syndromes characterized by platelet activation. Moreover, it is unclear whether the wide variations reported in the susceptibility of LDL from different individuals to oxidation ex vivo have any relevance to the actual extent of LDL oxidation in vivo.

In the present study, we used the urinary excretion of the F₂-isoprostane 8-iso-PGF₂ as a marker of in vivo lipid peroxidation.^{6 7} The measurement of this chemically stable compound has several distinct advantages over other markers of oxidant stress. (1) It reflects a nonenzymatic process of lipid peroxidation of an ubiquitous, endogenous substrate (ie, arachidonic acid) that is catalyzed by oxygen radicals.⁶ (2) Once released from cell membranes or LDL, 8-iso-PGF₂ circulates in peripheral venous blood.⁸ (3) Urinary excretion of this metabolite has been well characterized in humans.^{8 9} This analytical approach has been used previously to demonstrate enhanced lipid peroxidation in association with advanced age,⁹ cigarette smoking,^{10 11} diabetes mellitus,¹² and hypercholesterolemia,^{13 14} as well as after coronary artery reperfusion.^{24 25}

In the present study, we found that the formation and urinary excretion of 8-iso-PGF₂ are abnormally elevated in the vast majority of patients with severe unstable angina who were carefully characterized for other variables that could influence in vivo lipid peroxidation (Table ). This is the first report of enhanced in vivo lipid peroxidation in patients with unstable angina. Previously, Delanty et al²⁴ reported elevated levels of F₂-isoprostanes in patients with acute myocardial infarction who were undergoing thrombolysis.

We further examined whether enhanced F₂-isoprostane formation is a consequence of myocardial ischemia. The studies in patients with stable angina and active variant angina argue against this possibility by showing substantially unchanged rates of 8-iso-PGF₂ excretion up to 6 hours after exercise-induced myocardial ischemia (Figure 5) and during persistent transmural ischemia induced by coronary artery spasm. Similarly, Reilly et al²⁵ reported that patients undergoing coronary angioplasty for ischemic symptoms did not have elevated preprocedural levels of 8-iso-PGF₂.

Because platelet COX activity can be a source of relatively small amounts of 8-iso-PGF₂ compared with TXB₂,²⁶ we asked whether enhanced urinary excretion of the former and its correlation with TXM excretion in unstable angina might simply reflect an ongoing process of platelet activation in this setting. This seems unlikely because (1) platelet COX-1 activity was blocked by aspirin treatment in all patients and (2) aspirin-insensitive TXM excretion in unstable angina is likely to reflect extraplatelet sources of TXA₂ biosynthesis possibly driven by COX-2 induction.²⁷ Moreover, the study in patients with chronic stable angina that compared metabolite excretion in the presence and absence of platelet COX blockade by low-dose aspirin clearly shows that the suppression of TXA₂ biosynthesis is not associated with any detectable change in F₂-isoprostane formation (Figure 6). These results are consistent with a platelet COX-independent mechanism of formation of 8-iso-PGF₂ in ischemic heart disease, as demonstrated in other clinical settings.^{9 12 13}

The induction of PGHS-2 in monocytes/macrophages in response to a local inflammatory/mitogenic milieu can provide a source of aspirin-insensitive TXA₂ biosynthesis in unstable angina, as suggested previously²⁷ and confirmed in the present study. Moreover, the COX activity of monocyte PGHS-2 can also generate small amounts of 8-iso-PGF₂ in vitro.²² Thus, to exclude the contribution of an acute inflammatory reaction²⁸ to enhanced 8-iso-PGF₂ formation in unstable angina, we exploited the capacity of glucocorticoids to suppress monocyte PGHS-2 induction in response to lipopolysaccharide,²⁹ thereby preventing COX-2–dependent 8-iso-PGF₂ formation.²² The failure of intravenous 6-MP to suppress 8-iso-PGF₂ excretion in patients with unstable angina (Figure 7) argues against a COX-2–dependent mechanism of F₂-isoprostane formation in this setting.

Having established that enhanced excretion of 8-iso-PGF₂ is likely to reflect a nonenzymatic process of lipid peroxidation in patients with unstable angina, we examined the correlation between its rate of formation and plasma vitamin E levels. Vitamin E is a potent, lipid soluble antioxidant that is present in plasma and LDL. Our previous studies performed in hypercholesterolemic¹³ and diabetic¹² patients demonstrated dose-dependent reductions in F₂-isoprostane formation in response to short-term vitamin E supplementation. Consistent with these results, we found a statistically significant inverse correlation between plasma vitamin E levels and 8-iso-PGF₂ excretion rates in patients with unstable angina (Figure 4). Thus, most likely, enhanced lipid peroxidation in patients with severe unstable angina reflects an altered oxidant/antioxidant balance. The mechanism or mechanisms and location of the oxidant species responsible for increased formation of F₂-isoprostanes remain unanswered in the present study because of the obvious limitations inherent to urinary measurements. The localization of distinct isoprostanes³⁰ and other products of lipid peroxidation³¹ in carotid atherosclerotic lesions and their relationship to plaque instability³¹ suggest that a similar scenario may occur in coronary plaques.

In patients with unstable angina, 50% of the individual variation in aspirin-insensitive TXA₂ biosynthesis could be accounted for by the individual variation in 8-iso-PGF₂ formation (Figure 3). Although a common factor (eg, acute inflammation) might trigger both aspirin-insensitive TXA₂ biosynthesis and nonenzymatic formation of F₂-isoprostanes and thus contribute to the correlation between the 2, this seems unlikely in view of the intervention studies discussed earlier and of the correlation with endogenous vitamin E levels. A more likely explanation for this correlation between 8-iso-PGF₂ and TXM excretion, detectable in unstable angina but not in chronic stable angina, is that enhanced lipid peroxidation and formation of bioactive isoeicosanoids represent an important determinant of aspirin-insensitive TX biosynthesis. COX-2 induction in response to a variety of lipid mediators, including substrates, products, and inhibitors of PGH-synthase, has recently been described in mammary epithelial cells in vitro.³²

Concentrations of 8-iso-PGF₂ in the range of 1 nmol/L to 1 µmol/L induce a dose-dependent increase in platelet shape change, calcium release from intracellular stores, and inositol phosphates.⁷ Moreover, 8-iso-PGF₂ increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of nitric oxide.³³ Furthermore, 8-iso-PGF₂ causes dose-dependent, irreversible platelet aggregation in the presence of concentrations of collagen, ADP, arachidonic acid, and PGH₂/TXA₂ analogs that, when acting alone, fail to aggregate platelets.³⁴ Although platelet-active concentrations of 8-iso-PGF₂ may not be achieved in circulating blood, it should be pointed out that this compound is only 1 of a series of biologically active isoeicosanoids formed through a similar non-COX mechanism of lipid peroxidation.³⁵ In fact, up to 64 F₂-isoprostanes may be formed, and similar families of isomers of other prostaglandins and lipoxygenase and epoxygenase products are likely to be generated.³⁵ This level of complexity constrains the interpretation of studies that focus on a single isomer, particularly when attempting to define their likely role as bioactive autacoids in vivo. Thus, both PGHS-2–derived TXA₂ and nonenzymatic F₂-isoprostane formation might represent 2 important eicosanoid mechanisms that contribute to aspirin-insensitive platelet activation in unstable angina. The 2 mechanisms might play a variable role in different patients with unstable angina, depending on the prevalence of an acute inflammatory reaction and its endogenous modulation versus enhanced oxidant stress and its endogenous regulation.

We conclude that increased nonenzymatic formation of F₂-isoprostanes may provide an important biochemical link between an altered oxidant/antioxidant balance and aspirin-insensitive TX biosynthesis in patients with unstable angina. These results provide a rationale for dose-finding studies of antioxidants in acute coronary syndromes, with F₂-isoprostane formation used as the primary biochemical end point.

	Acknowledgments

 
This work was supported by grants from Consiglio Nazionale delle Ricerche (Progetto Strategico "Infarto" 96.052685T74) and MURST ("Meccanismi Patogenetici dell’infarto Miocardico" C.I.P 9706570507-005). The expert editorial assistance of Daniela Basilico is gratefully acknowledged.

Received December 30, 1999; revision received March 23, 2000; accepted March 27, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Kostner K, Hornykewycz S, Yang P, et al. Is oxidative stress causally linked to unstable angina pectoris? A study in 100 CAD patients and matched controls. Cardiovasc Res. 1997;36:330–336.[Abstract/Free Full Text]

2. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487–1494.[Abstract/Free Full Text]

3. Vita JA, Keaney JF, Raby KE, et al. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol. 1998;31:980–986.[Abstract/Free Full Text]

4. Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease. Ann Intern Med. 1995;123:860–872.[Abstract/Free Full Text]

5. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–786.[Medline] [Order article via Infotrieve]

6. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F₂-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383–9387.[Abstract/Free Full Text]

7. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997;17:2309–2315.[Abstract/Free Full Text]

8. Awad JA, Morrow JD, Takahashi K, et al. Identification of non-cyclooxygenase-derived prostanoid (F₂-isoprostane) metabolites in human urine and plasma. J Biol Chem. 1993;268:4161–4169.[Abstract/Free Full Text]

9. Wang Z, Ciabattoni G, Crèminon C, et al. Immunological characterization of urinary 8-epi-PGF₂ excretion in man. J Pharmacol Exp Ther. 1995;275:94–100.[Abstract/Free Full Text]

10. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F₂-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198–1103.[Abstract/Free Full Text]

11. Reilly M, Delanty N, Lawson JA, et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94:19–25.[Abstract/Free Full Text]

12. Davì G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F₂ and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224–229.[Abstract/Free Full Text]

13. Davì G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-epi-PGF₂ is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230–3235.[Abstract/Free Full Text]

14. Reilly MP, Delanty N, Tremoli E, et al. Increased formation of distinct F₂ isoprostanes in hypercholesterolemia. Circulation. 1998;98:2822–2828.[Abstract/Free Full Text]

15. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983–989.[Abstract]

16. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 1990;63:163–168.[Medline] [Order article via Infotrieve]

17. Braunwald E. Unstable angina. Circulation. 1989;80:410–414.[Free Full Text]

18. Lee BL, Chua SC, Ong HY, et al. High-performance liquid chromatographic method for routine determination of vitamins A and E and ß carotene in plasma. J Chromatogr. 1992;581:41–47.[Medline] [Order article via Infotrieve]

19. Ciabattoni G, Maclouf J, Catella F, et al. Radioimmunoassay of 11-dehydro-TXB₂ in human plasma and urine. Biochim Biophys Acta. 1987;918:293–297.[Medline] [Order article via Infotrieve]

20. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets: acetylation of a particular protein fraction. J Clin Invest. 1975;56:624–632.

21. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366–1372.

22. Patrignani P, Santini G, Panara MR, et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F₂-isoprostanes formation. Br J Pharmacol. 1996;118:1285–1293.[Medline] [Order article via Infotrieve]

23. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2994–2998.[Abstract/Free Full Text]

24. Delanty N, Reilly M, Praticò D, et al. 8-Epi-PGF₂ generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation.. 1997;96:2492–2499.

25. Reilly MP, Delanty N, O’Callaghan P, et al. Increased generation of the F₂ isoprostanes, IPF₂-1 and 8-iso-PGF₂, in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. 1997;96:3314–3320.[Abstract/Free Full Text]

26. Praticò D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane 8-epi-prostaglandin F₂. J Biol Chem. 1995;270:9800–9808.[Abstract/Free Full Text]

27. Cipollone F, Patrignani P, Greco A, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 1997;96:1109–1116.[Abstract/Free Full Text]

28. Liuzzo G, Biasucci LM, Gallimore R, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417–424.[Abstract/Free Full Text]

29. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705–1712.[Abstract/Free Full Text]

30. Praticò D, Iuliano L, Mauriello A, et al. Localization of distinct F₂-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997;100:2028–2034.[Medline] [Order article via Infotrieve]

31. Mallat Z, Nakamura T, Ohan J, et al. The relationship of hydroxyeicosatetraenoic acids and F₂-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest. 1999;103:421–427.[Medline] [Order article via Infotrieve]

32. Meade EA, McIntyre TM, Zimmerman GA, et al. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem. 1999;274:8328–8334.[Abstract/Free Full Text]

33. Minuz P, Andrioli G, Degan M, et al. The F₂-isoprostane 8-epi-PGF₂ increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of nitric oxide. Arterioscler Thromb Vasc Biol. 1998;18:1248–1256.[Abstract/Free Full Text]

34. Praticò D, Smyth EM. Violi F, et al. Local amplification of platelet function by 8-epi-prostaglandin F₂ is not mediated by thromboxane receptor isoforms. J Biol Chem. 1996;271:14916–14924.[Abstract/Free Full Text]

35. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost. 1998;79:691–670.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]

				C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]

				A. M. Friel, P. G. Hynes, D. J. Sexton, T. J. Smith, and J. J. Morrison Expression Levels of mRNA for Rho A/Rho Kinase and Its Role in Isoprostane-Induced Vasoconstriction of Human Placental and Maternal Vessels Reproductive Sciences, February 1, 2008; 15(2): 179 - 188. [Abstract] [PDF]

				Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]

				A. O. Maree and D. J. Fitzgerald Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease Circulation, April 24, 2007; 115(16): 2196 - 2207. [Full Text] [PDF]

				D. Cox, A. O. Maree, M. Dooley, R. Conroy, M. F. Byrne, and D. J. Fitzgerald Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers Stroke, August 1, 2006; 37(8): 2153 - 2158. [Abstract] [Full Text] [PDF]

				D. J. Angiolillo, E. Bernardo, C. Ramirez, M. A. Costa, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al. Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment J. Am. Coll. Cardiol., July 18, 2006; 48(2): 298 - 304. [Abstract] [Full Text] [PDF]

				A. M Friel, D. J Sexton, M. W O'Reilly, T. J Smith, and J. J Morrison Rho A/Rho kinase: human umbilical artery mRNA expression in normal and pre eclamptic pregnancies and functional role in isoprostane-induced vasoconstriction Reproduction, July 1, 2006; 132(1): 169 - 176. [Abstract] [Full Text] [PDF]

				I. M. Robbins, S. M. Kawut, D. Yung, M. P. Reilly, W. Lloyd, G. Cunningham, J. Loscalzo, S. E. Kimmel, B. W. Christman, and R. J. Barst A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur. Respir. J., March 1, 2006; 27(3): 578 - 584. [Abstract] [Full Text] [PDF]

				R. P Raghavan, D. W Laight, K. M Shaw, and M. H Cummings Review: Aspirin and diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2): 74 - 82. [Abstract] [PDF]

				C. Patrono, L. A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med., December 1, 2005; 353(22): 2373 - 2383. [Full Text] [PDF]

				D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al. Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment Diabetes, August 1, 2005; 54(8): 2430 - 2435. [Abstract] [Full Text] [PDF]

				J. Hanson, S. Rolin, D. Reynaud, N. Qiao, L. P. Kelley, H. M. Reid, F. Valentin, J. Tippins, B. T. Kinsella, B. Masereel, et al. In Vitro and in Vivo Pharmacological Characterization of BM-613 [N-n-Pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 293 - 301. [Abstract] [Full Text] [PDF]

				P. Ferroni, S. Novo, V. Davi, G. Novo, S. Basili, G. Davi, F. Cipollone, and A. Mezzetti Circulating Transforming Growth Factor-{beta}1 Levels in Asymptomatic Carotid Plaques * Response: Stroke, March 1, 2005; 36(3): 525 - 526. [Full Text] [PDF]

				S. Sanderson, J. Emery, T. Baglin, and A.-L. Kinmonth Narrative Review: Aspirin Resistance and Its Clinical Implications Ann Intern Med, March 1, 2005; 142(5): 370 - 380. [Abstract] [Full Text] [PDF]

				M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]

				S. P. Schulman Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, October 20, 2004; 292(15): 1875 - 1882. [Abstract] [Full Text] [PDF]

				C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]

				F. Cipollone, E. Toniato, S. Martinotti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, S. Ursi, G. Vitullo, M. Averna, et al. A Polymorphism in the Cyclooxygenase 2 Gene as an Inherited Protective Factor Against Myocardial Infarction and Stroke JAMA, May 12, 2004; 291(18): 2221 - 2228. [Abstract] [Full Text] [PDF]

				K. Greaves, S. R Dixon, I. O. Coker, A. I Mallet, M. Vkiran, M. J Shattock, M. J Fejka, W. W O'Neill, R. Senior, S. Redwood, et al. Influence of isoprostane F2{alpha}-III on reflow after myocardial infarction Eur. Heart J., May 2, 2004; 25(10): 847 - 853. [Abstract] [Full Text] [PDF]

				E. Schwedhelm, A. Bartling, H. Lenzen, D. Tsikas, R. Maas, J. Brummer, F.-M. Gutzki, J. Berger, J. C. Frolich, and R. H. Boger Urinary 8-iso-Prostaglandin F2{alpha} as a Risk Marker in Patients With Coronary Heart Disease: A Matched Case-Control Study Circulation, February 24, 2004; 109(7): 843 - 848. [Abstract] [Full Text] [PDF]

				F. Cipollone, B. Rocca, and C. Patrono Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 246 - 255. [Abstract] [Full Text]

				C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, B. Charbonnier, D. Fitzgerald, J. Hirsh, S. Husted, J. Kvasnicka, et al. Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology Eur. Heart J., January 2, 2004; 25(2): 166 - 181. [Full Text] [PDF]

				F. Cipollone, C. Ferri, G. Desideri, L. Paloscia, G. Materazzo, M. Mascellanti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, et al. Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty Circulation, December 2, 2003; 108(22): 2776 - 2782. [Abstract] [Full Text] [PDF]

				K. K. Griendling and G. A. FitzGerald Oxidative Stress and Cardiovascular Injury: Part II: Animal and Human Studies Circulation, October 28, 2003; 108(17): 2034 - 2040. [Full Text] [PDF]

				L. Belhassen, G. Pelle, J.-L. Dubois-Rande, and S. Adnot Improved endothelial function by the thromboxane a2 receptor antagonist s 18886 in patients with coronary artery disease treated with aspirin J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1198 - 1204. [Abstract] [Full Text] [PDF]

				M. Valgimigli, L. Agnoletti, S. Curello, L. Comini, G. Francolini, F. Mastrorilli, E. Merli, R. Pirani, G. Guardigli, P. G. Grigolato, et al. Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells: A Possible Link to Pan-Coronary Syndromes Circulation, January 21, 2003; 107(2): 264 - 270. [Abstract] [Full Text] [PDF]

				F. Cipollone, A. Ganci, A. Greco, M. R. Panara, M. Pasquale, D. Di Gregorio, E. Porreca, A. Mezzetti, F. Cuccurullo, and P. Patrignani Modulation of Aspirin-Insensitive Eicosanoid Biosynthesis by 6-Methylprednisolone in Unstable Angina Circulation, January 7, 2003; 107(1): 55 - 61. [Abstract] [Full Text] [PDF]

				P. Minuz, P. Patrignani, S. Gaino, M. Degan, L. Menapace, R. Tommasoli, F. Seta, M. L. Capone, S. Tacconelli, S. Palatresi, et al. Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease Circulation, November 26, 2002; 106(22): 2800 - 2805. [Abstract] [Full Text] [PDF]

				R. De Caterina, F. Cipollone, F. P. Filardo, M. Zimarino, W. Bernini, G. Lazzerini, T. Bucciarelli, A. Falco, P. Marchesani, R. Muraro, et al. Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F2-Isoprostane Formation in Hypercholesterolemic Subjects: No Further Effect of Vitamin E Circulation, November 12, 2002; 106(20): 2543 - 2549. [Abstract] [Full Text] [PDF]

				B. Rocca, P. Secchiero, G. Ciabattoni, F. O. Ranelletti, L. Catani, L. Guidotti, E. Melloni, N. Maggiano, G. Zauli, and C. Patrono Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets PNAS, May 28, 2002; 99(11): 7634 - 7639. [Abstract] [Full Text] [PDF]

				C. Patrono Antiplatelet strategies Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A42 - A47. [Abstract] [PDF]

				M. Dietrich, G. Block, M. Hudes, J. D. Morrow, E. P. Norkus, M. G. Traber, C. E. Cross, and L. Packer Antioxidant Supplementation Decreases Lipid Peroxidation Biomarker F2-isoprostanes in Plasma of Smokers Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 7 - 13. [Abstract] [Full Text]

				P. McNamara and G. A. FitzGerald Smoking-Induced Vascular Disease: A New Twist on an Old Theme Circ. Res., September 28, 2001; 89(7): 563 - 565. [Full Text] [PDF]

				L. J. Janssen Isoprostanes: an overview and putative roles in pulmonary pathophysiology Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1067 - L1082. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cipollone, F. Articles by Patrono, C. Search for Related Content PubMed PubMed Citation Articles by Cipollone, F. Articles by Patrono, C. Related Collections Acute coronary syndromes